Samsung Bioepis' biosimilar sales in European Union surpassed $390 million in the first half of this year, data showed Thursday.
|Samsung Bioepis' biosimilar sales in Europe reached $390 million in the first-half of 2020. (Samsung Bioepis)|
According to the earnings report of Biogen, Samsung Bioepis' marketing partner in EU, the sales of three biosimilar products – Benepali, Flixabi, and Imraldi -- totaled $390.4 million in the first half of 2020, up 9 percent from the same period of last year.
The sales of Benepali (Ingredient: Etanercept) totaled $239 million, and those of Flixabi (Ingredient: Infliximab) and Imraldi (Ingredient: adalimumab) amounted to $44 million and $106 million, respectively.
Benepali showed the highest growth among the three. The biosimilar’s accumulated sales reached about 2 trillion won ($1.6 billion) since it started marketing in Europe in 2016.
"As of April, the market share gap between Benepali and Enbrel, the original drug, in Europe is about 0.5 percent," the company said. "In the competitive Humira biosimilar market, Samsung Bioepis' Imraldi also occupies more than 30 percent share."
Despite the increased sales in the first half-year, the three biosimilars posted the second-quarter sales of $171.6 million, a 7 percent drop from the same period last year.
"The sales decline in the second quarter, but the first quarter's robust performance pushed up the six-month figure," a company official said. "Due to Covid-19 outbreak during the first quarter, the company actively responded to requests for preemptive shipments, which helped us record the highest sales in its history."
<© Korea Biomedical Review, All rights reserved.>